Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)

Inclusion Criteria: * Signed and dated written informed consent by the subject or his/her legally authorized representative; * Modified Rankin (mRankin) score of 0 or 1 prior to the onset of subarachnoid hemorrhage; * Ruptured aneurysm secured by endovascular coil embolization or surgical clipping (the Procedure), not more than 72 hours after the onset of subarachnoid hemorrhage; and * Hunt and Hess (H\&H) grade 3 or 4, or World Federation of Neurological Surgeons (WFNS) score 3 or 4 prior to the Procedure, and Modified Fisher (mFisher) grade 3 or 4, prior to the Procedure; or * Clinical signs of ("symptomatic") delayed cerebral ischemia; or * Angiographic evidence of cerebral vasospasm Exclusion Criteria: * In the judgment of the Investigator the patient is not a good candidate for the study * Evidence of rebleed following the Procedure * Subarachnoid hemorrhage secondary to trauma or to arteriovenous malformation * Diagnosed moderate to severe pulmonary hypertension * Radiologically confirmed moderate to severe pulmonary edema (as shown by the presence of Kerley lines, peribronchial cuffing, thickened interlobar fissure, consolidation and/or pleural effusion) * History within the past 6 months and/or finding of decompensated heart failure * Acute myocardial infarction within 3 months prior to the administration of the study drug * Left ventricular ejection fraction \<40%, as determined by prior echocardiography or clinical signs of CHF * Medical history or concurrent evidence of moderate to severe renal insufficiency (estimated creatinine clearance \< 30 mL/min)